

Javier Martín Broto *Curriculum Vitae*: version of May 26, 2022



Javier Martín Broto MD, PhD.

Fundación Jimenez Diaz University
Hospital, Avda de los Reyes Católicos, 2
28040 - Madrid, Spain
+34 955923113 - +34 629108979
jmartin@atbsarc.org
ORCID iD: 0000-0001-7350-6916

PROFESSIONAL SUMMARY

Dr Javier Martin Broto is a medical oncologist at the Fundación Jimenez Diaz University Hospital, and he is leading, at the Fundación Jiménez Díaz Institute for Medical Research (IIS-FJD), Madrid (Spain) the lab team of the Advanced Therapies and Biomarkers in Sarcoma (ATBSarc).

He was born 57 years ago in Huesca province, Spain. He studied Medicine between 1982 and 1988 in the School of Medicine of Zaragoza, obtaining the official title of Specialist in Medical Oncology in Son Dureta Hospital, Palma de Mallorca, in 1994 after successfully passing a national exam. From 1994 to 2014 devoted to sarcoma care in this Hospital that became part of Center of Reference for Sarcoma. From September 2014 he moved to University Hospital of Virgen del Rocio in Sevilla to coordinate the multidisciplinary sarcoma team and to apply for a selective number of centers of reference in Sarcoma Care in our Country. Finally, this Center was accredited as National Health System Reference Center for Sarcoma Care (along with other 4 Hospitals). Likewise, this Center is one accredited within ERN (European Network for Rare Diseases) as European Center of Reference in Sarcoma from 2017. In 2021, he moved to the Fundación Jimenez Diaz University Hospital. Founder Member of the Spanish Group for Research on Sarcomas (GEIS) in 1994 and currently vice-chairman of this group from 2019 (He was GEIS Chairman from 2010 to 2018). He obtained PhD degree on Molecular Biology in 2010 focusing on molecular prognostic biomarkers in GIST. Member of American Society of Clinical Oncology (ASCO), of European Society of Medical Oncology (ESMO) where is chair of sarcoma track, of Connective Tissue Oncology Society (CTOS), of Sociedad Española de Oncología Médica (SEOM). ESMO Faculty member in Sarcomas from 2010 and he was member of board directors of CTOS from 2014 to 2018. He is member of Steering committee of EURACAN network.

Currently he combines clinical sarcoma assistance with translational research, leading a basic research team in the lab. Additionally, he's running and designing several trials on sarcoma patients, some of them as coordinator at national and international level. He is the author/co-author of more than 100 manuscripts in sarcoma including first author in journals as Journal Clinical Oncology, Lancet Oncology, JAMA Oncology, Annals of Oncology, and Clinical Cancer Research among others. He is leading the consortium SELNET through Horizon 2020 grant; this network involves Latin-American and European countries.

SKILL HIGHLIGHTS

Oncology specialist

High dedication to patient-care

Leadership

Translational research profile

Extensive cancer gene understanding

Signaling pathways based knowledge

Great knowledge in molecular biology

High ethical standards

Collaborative

Business-minded practice

Expertise in PET scan and CT scan analysis

Pathological comprehension

High level of English

PROFESSIONAL EXPERIENCE

Medical Oncologist – Medical Board Number 0704499

April 2021 to current

Fundación Jimenez Diaz University Hospital, Madrid, Spain

Villalba General Hospital, Madrid, Spain

Coordinator of the Sarcoma European & LatinAmerican NETwork (SELNET)

January 2019 to current

Fundación Jiménez Díaz Institute for Medical Research, Madrid, Spain

Medical Oncologist – Medical Board Number 0704499

September 2014 to 2020

University Hospital Virgen Del Rocío, Sevilla, Spain

Research Group Leader

September 2014 to current

Group of Advanced Therapies and Biomarkers in Sarcoma (TERABIS) – Laboratory 214

Institute of Biomedicine of Seville, Sevilla, Spain

Medical Oncologist

November 2010 to August 2014

University Hospital Son Espases, Palma, Spain

Coordinator of the multidisciplinary committee of tumors of skeletal muscle (COTMES)

September 2014 to December 2020

University Hospital Virgen Del Rocío, Sevilla, Spain

Chairman of the Spanish Group for Research on Sarcomas (GEIS)

2010 to 2018

Medical Director

2004 to 2007 (at same time that medical oncologist)

University Hospital Son Dureta, Palma, Spain

Medical Oncologist

January 1994 to October 2010

University Hospital Son Dureta, Palma, Spain

Médico Residente en Oncología

January 1991 to December 1994

Área de Oncología Hospital Universitario Son Dureta

EDUCATION AND TRAINING

PhD in Health Sciences

Balearic Islands University, Palma, Spain. July 14, 2009

Medical Oncology Internal Resident

University hospital Son Dureta, Palma, Spain. July 31, 1994

Degree in Medicine

University of Zaragoza, Zaragoza, Spain. June 30, 1988

RESEARCH ACTIVITIES

Peer-Reviewed Publications in the past 3 years

1. J Y Blay, E Palmerini, J Bollard, S Aguiar, M Angel, B Araya, R Badilla, D Bernabeu, F Campos, Caro-Sánchez Chs, A Carvajal Montoya, S Casavilca-Zambrano, Castro-Oliden V, M Chacón, M A Clara-Altamirano, P Collini, R Correa Genoroso, F D Costa, M Cuellar, A P Dei Tos, H R Dominguez Malagon, D M Donati, A Dufresne, M Eriksson, M Farias-Loza, A M Frezza, T Frisoni, D Y Garcia-Ortega, H Gerderblom, F Gouin, M C Gómez-Mateo, A Gronchi, J Haro, N Hindi, L Huanca, N Jimenez, M Karanian, B Kasper, A Lopes, B B Lopes David, A Lopez-Pousa, G Lutter, R G Maki, H Martinez-Said, J L Martinez-Tlahuel, C A Mello, J M Morales Pérez, D S Moura, S A Nakagawa, A G Nascimento, E J Ortiz-Cruz, S Patel, Y Pfluger, S Provenzano, A Righi, A Rodriguez, T G Santos, K Scotlandi, Silva Mlg, T Soulé, S Stacchiotti, C M Valverde, F Waisberg, E Zamora Estrada, **J Martín-Broto**. SELNET clinical practice guidelines for bone sarcoma. *Crit Rev Oncol Hematol*. 2022 Apr 21;174:103685. doi: 10.1016/j.critrevonc.2022.103685
2. Mrinal M Gounder, Albiruni Abdul Razak, Neeta Somaiah, Sant Chawla, **Javier Martín-Broto**, Giovanni Grignani, Scott M Schuetze, Bruno Vincenzi, Andrew J Wagner, Bartosz Chmielowski, Robin L Jones, Richard F Riedel, Silvia Stacchiotti, Elizabeth T Loggers, Kristen N Ganjoo, Axel Le Cesne, Antoine Italiano, Xavier Garcia Del Muro, Melissa Burgess, Sophie Piperno-Neumann, Christopher Ryan, Mary F Mulcahy, Charles Forscher, Nicolas Penel, Scott Okuno, Anthony Elias, Lee Hartner, Tony Philip, Thierry Alcindor, Bernd Kasper, Peter Reichardt, Lore Lapeire, Jean-Yves Blay, Christine Chevreau, Claudia Maria Valverde Morales, Gary K Schwartz, James L Chen, Hari Deshpande, Elizabeth J Davis, Garth Nicholas, Stefan Gröschel, Helen Hatcher, Florence Duffaud, Antonio Casado Herráez, Roberto Diaz Beveridge, Giuseppe Badalamenti, Mikael Eriksson, Christian Meyer, Margaret von Mehren, Brian A Van Tine, Katharina Götze, Filomena Mazzeo, Alexander Jakobson, Aviad Zick, Alexander Lee, Anna Estival Gonzalez, Andrea Napolitano, Mark A Dickson, Dayana Michel, Changting Meng, Lingling Li, Jianjun Liu, Osnat Ben-Shahar, Dane R Van Domelen, Christopher J Walker, Hua Chang, Yosef Landesman, Jatin J Shah, Sharon Shacham, Michael G Kauffman, Steven Attia. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. *J Clin Oncol*. 2022 Apr 8;JCO2101829. doi: 10.1200/JCO.21.01829.
3. E Palassini, O Mir, G Grignani, B Vincenzi, H Gelderblom, A Sebio, C Valverde, G G Baldi, A Brunello, G G Cardellino, A Marrari, G Badalamenti, **J Martín-Broto**, V Ferraresi, M Libertini, S Turano, I Gataa, P Collini, A P Dei Tos, M Gennaro, F Bini, S Provenzano, S Lo Vullo, L Mariani, A Le Cesne, P G Casali. Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses. *Breast Cancer Res Treat*. 2022 Apr;192(3):603-610. doi: 10.1007/s10549-022-06524-4.
4. J.Y. Blay, N. Hindi, J. Bollard, S. Aguiar Jr. M. Angel, B. Araya, R. Badilla, D. Bernabeu, F. Campos, C.H.S. Caro-Sánchez, B. Carvajal, A. Carvajal Montoya, S. Casavilca-Zambrano, V. Castro-Oliden, M. Chacón, M. Clara, P. Collini, R. Correa Genoroso, F.D. Costa, M. Cuellar, A.P. dei Tos, H.R. Dominguez Malagon, D. Donati, A. Dufresne, M. Eriksson, M. Farias-Loza, P. Fernandez, A.M. Frezza, T. Frisoni, D.Y. Garcia-Ortega, H. Gelderblom, F. Gouin, M.C. Gómez-Mateo, A. Gronchi, J. Haro, L. Huanca, N. Jimenez, M. Karanian, B. Kasper, B.B. Lopes David, A. Lopez-Pousa, G. Lutter, H. Martinez-Said, J. Martinez-Tlahuel, C.A. Mello, J.M. Morales Pérez, S. Moura David, A.G. Nascimento, E.J. Ortiz-Cruz, E. Palmerini, S. Patel, Y. Pfluger, S. Provenzano, A. Righi, A. Rodriguez, R. Salas, T.T.G. Santos, K. Scotlandi, T. Soule, S. Stacchiotti, C. Valverde, F. Waisberg, E. Zamora Estrada, **J. Martín-Broto**. SELNET clinical practice guidelines for soft tissue sarcoma and GIST. *Cancer Treatment Reviews*. Volume 102, 102312, January 01, 2022. DOI:https://doi.org/10.1016/j.ctrv.2021.102312
5. **Javier Martín-Broto**, Maria Lopez-Alvarez, David S Moura, Rafael Ramos, Paola Collini, Cleofe Romagosa, Silvia Bagué, Salvatore L Renne, Marta Barisella, Valerie Velasco, Jean-Michel Coindre, Daniel Lopez-Lopez, Joaquin Dopazo, Marco Gambarotti, Luca Braglia, Domenico Franco Merlo, Emanuela Palmerini, Silvia Stacchiotti, Vittorio L Quagliuolo, Antonio Lopez-Pousa, Giovanni Grignani, Jean-Yves Blay, Antonella Brunello, Antonio Gutierrez, Claudia Valverde, Nadia Hindi, Angelo Paolo Dei Tos, Piero Picci, Paolo G Casali, Alessandro Gronchi. Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STs 1001 Randomized Phase III Trial. *Mol Cancer Ther*. 2021 Sep 22. doi: 10.1158/1535-7163.MCT-21-0315.
6. Sandro Pasquali, Emanuela Palmerini, Vittorio Quagliuolo, **Javier Martín-Broto**, Antonio Lopez-Pousa, Giovanni Grignani, Antonella Brunello, Jean-Yves Blay, Oscar Tendero, Robert Diaz-Beveridge, Virginia Ferraresi, Iwona Lugowska, Gabriele Infante, Luca Braglia, Domenico Franco Merlo, Valeria Fontana, Emanuela Marchesi, Davide Maria Donati, Elena Palassini, Giuseppe Bianchi, Andrea Marrari, Carlo Morosi, Silvia Stacchiotti, Silvia Bagué, Jean Michel Coindre, Angelo Paolo Dei Tos, Piero Picci, Paolo Bruzzi, Rosalba Miceli, Paolo Giovanni Casali, Alessandro Gronchi. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STs 1001 randomized trial. *Cancer*. 2022 Jan 1;128(1):85-93. doi: 10.1002/cncr.33895. Epub 2021 Oct 13

7. Esther Martinez-Font, Marina Pérez-Capó, Oliver Vögler, **Javier Martín-Broto**, Regina Alemany, Antònia Obrador-Hevia. WNT/ β -Catenin Pathway in Soft Tissue Sarcomas: New Therapeutic Opportunities? *Cancers (Basel)*. 2021 Nov 3;13(21):5521. doi: 10.3390/cancers13215521
8. Bruno Vincenzi, Andrea Napolitano, Marta Fiocco, Olivier Mir, Piotr Rutkowski, Jean-Yves Blay, Peter Reichardt, Heikki Joensuu, Elena Fumagalli, Spyridon Gennatas, Nadia Hindi, Margherita Nannini, Mariella Spalato Ceruso, Antoine Italiano, Giovanni Grignani, Antonella Brunello, Silvia Gasperoni, Tommaso De Pas, Giuseppe Badalamenti, Maria A Pantaleo, Winan J van Houdt, Nikki S IJzerman, Neeltje Steeghs, Hans Gelderblom, Ingrid M E Desar, Johanna Falkenhorst, Marianna Silletta, Marta Sbaraglia, Giuseppe Tonini, **Javier Martín-Broto**, Peter Hohenberger, Axel Le Cesne, Robin L Jones, Angelo P Dei Tos, Alessandro Gronchi, Sebastian Bauer, Paolo G Casali. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. *Clin Cancer Res*. 2021 Oct 6. doi: 10.1158/1078-0432.CCR-21-1665
9. Carlos Torrado, Nadia Hindi, Gema Civantos, David S. Moura, **Javier Martín-Broto**. Pazopanib For The Treatment of Malignant Granular Cell Tumors: Case Report and Review of The Literature. *Case Report, Clin Oncol Case Rep Vol: 4 Issue: 10*
10. **Javier Martín-Broto**, Patrick M Peterson, Gerard J Oakley, Matteo Ceccarelli, Robin L Jones. Olaratumab-induced Biomarker Modulation in Sarcomas-Response. *Mol Cancer Ther*. 2021 Oct;20(10):2094. doi: 10.1158/1535-7163.MCT-21-0497
11. P G Casali, J Y Blay, N Abecassis, J Bajpai, S Bauer, R Biagini, S Bielack, S Bonvalot, I Boukovinas, J V M G Bovee, K Boye, T Brodowicz, A Buonadonna, E De Álava, A P Dei Tos, X G Del Muro, A Dufresne, M Eriksson, A Fedenko, V Ferraresi, A Ferrari, A M Frezza, S Gasperoni, H Gelderblom, F Gouin, G Grignani, R Haas, A B Hassan, N Hindi, P Hohenberger, H Joensuu, R L Jones, C Jungels, P Jutte, B Kasper, A Kawai, K Kopeckova, D A Krákorová, A Le Cesne, F Le Grange, E Legius, A Leithner, A Lopez-Pousa, **J Martín-Broto**, O Merimsky, C Messiou, A B Miah, O Mir, M Montemurro, C Morosi, E Palmerini, M A Pantaleo, R Piana, S Piperno-Neumann, P Reichardt, P Rutkowski, A A Safwat, C Sangalli, M Sbaraglia, S Scheipl, P Schöffski, S Sleijfer, D Strauss, S J Strauss, K Sundby Hall, A Trama, M Unk, M A J van de Sande, W T A van der Graaf, W J van Houdt, T Frebourg, A Gronchi, S Stacchiotti. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2022 Jan;33(1):20-33. doi: 10.1016/j.annonc.2021.09.005
12. S J Strauss, A M Frezza, N Abecassis, J Bajpai, S Bauer, R Biagini, S Bielack, J Y Blay, S Bolle, S Bonvalot, I Boukovinas, J V M G Bovee, K Boye, B Brennan, T Brodowicz, A Buonadonna, E de Álava, A P Dei Tos, X Garcia Del Muro, A Dufresne, M Eriksson, F Fagioli, A Fedenko, V Ferraresi, A Ferrari, N Gaspar, S Gasperoni, H Gelderblom, F Gouin, G Grignani, A Gronchi, R Haas, A B Hassan, S Hecker-Nolting, N Hindi, P Hohenberger, H Joensuu, R L Jones, C Jungels, P Jutte, L Kager, B Kasper, A Kawai, K Kopeckova, D A Krákorová, A Le Cesne, F Le Grange, E Legius, A Leithner, A López Pousa, **J Martín-Broto**, O Merimsky, C Messiou, A B Miah, O Mir, M Montemurro, B Morland, C Morosi, E Palmerini, M A Pantaleo, R Piana, S Piperno-Neumann, P Reichardt, P Rutkowski, A A Safwat, C Sangalli, M Sbaraglia, S Scheipl, P Schöffski, S Sleijfer, D Strauss, K Sundby Hall, A Trama, M Unk, M A J van de Sande, W T A van der Graaf, W J van Houdt, T Frebourg, R Ladenstein, P G Casali, S Stacchiotti. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol*. 2021 Dec;32(12):1520-1536. doi: 10.1016/j.annonc.2021.08.1995.
13. Javier Martínez-Trufero, Josefina Cruz Jurado, C Nieves Hernández-León, Raquel Correa, Jose Manuel Asencio, Daniel Bernabeu, Rosa Alvarez, Nadia Hindi, Cristina Mata, Gloria Marquina, Virginia Martínez, Andres Redondo, Luis Javier Floría, M Carmen Gómez-Mateo, Javier Lavernia, Ana Sebio, Xavier Garcia Del Muro, **Javier Martín-Broto**, Claudia Valverde-Morales. Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations. Spanish Group for Sarcoma research (GEIS - GROUP). Part II. *Cancer Treat Rev*. 2021 Sep;99:102260. doi: 10.1016/j.ctrv.2021.102260.
14. Javier Martínez-Trufero, Josefina Cruz Jurado, M Carmen Gómez-Mateo, Daniel Bernabeu, Luis Javier Floría, Javier Lavernia, Ana Sebio, Xavier García Del Muro, Rosa Álvarez, Raquel Correa, C Nieves Hernández-León, Gloria Marquina, Nadia Hindi, Andrés Redondo, Virginia Martínez, Jose Manuel Asencio, Cristina Mata, Claudia M Valverde Morales, **Javier Martín-Broto**. Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS - GROUP). Part I. *Cancer Treat Rev*. 2021 Sep;99:102259. doi: 10.1016/j.ctrv.2021.102259.
15. A Gronchi, A B Miah, A P Dei Tos, N Abecassis, J Bajpai, S Bauer, R Biagini, S Bielack, J Y Blay, S Bolle, S Bonvalot, I Boukovinas, J V M G Bovee, K Boye, B Brennan, T Brodowicz, A Buonadonna, E De Álava, X G Del Muro, A Dufresne, M Eriksson, F Fagioli, A Fedenko, V Ferraresi, A Ferrari, A M Frezza, S Gasperoni, H Gelderblom, F Gouin, G Grignani, R Haas, A B Hassan, S Hecker-Nolting, N Hindi, P Hohenberger, H Joensuu, R L Jones, C Jungels, P Jutte, L Kager, B Kasper, A Kawai, K Kopeckova, D A Krákorová, A Le Cesne, F Le Grange, E Legius, A Leithner, A Lopez-Pousa, **J Martín-Broto**, O Merimsky, C Messiou, O Mir, M Montemurro, B Morland, C Morosi, E Palmerini, M A Pantaleo, R Piana, S Piperno-Neumann, P Reichardt, P Rutkowski, A A Safwat, C Sangalli, M Sbaraglia, S Scheipl, P Schöffski, S Sleijfer, D Strauss, S Strauss, K Sundby Hall, A Trama, M Unk, M A J van de Sande, W T A van der Graaf, W J van

- Houdt, T Frebourg, P G Casali, S Stacchiotti. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2021 Jul 22;S0923-7534(21)02184-0.
16. David S. Moura, Juan Díaz-Martín, Silvia Bagué, Ruth Orellana-Fernandez, Ana Sebio, Jose L. Mondaza-Hernandez, Carmen Salguero-Aranda, Federico Rojo, Nadia Hindi, Christopher D.M. Fletcher, **Javier Martín-Broto**. A novel *NFIX-STAT6* gene fusion in solitary fibrous tumor: a case report. *Int J Mol Sci.* 2021 Jul 13;22(14):7514. doi: 10.3390/ijms22147514.
 17. **Martin-Broto J**, Mondaza-Hernandez JL, Moura DS, Hindi N. A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons. *Cancers (Basel).* 2021 Jun 10;13(12):2913. doi: 10.3390/cancers13122913
 18. Stacchiotti S, Miah AB, Frezza AM, Messiou C, Morosi C, Caraceni A, Antonescu CR, Bajpai J, Baldini E, Bauer S, Biagini R, Bielack S, Blay JY, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brodowicz T, Callegaro D, De Alava E, Deoras-Sutliff M, Dufresne A, Eriksson M, Errani C, Fedenko A, Ferraresi V, Ferrari A, Fletcher CDM, Garcia Del Muro X, Gelderblom H, Gladdy RA, Gouin F, Grignani G, Gutkovich J, Haas R, Hindi N, Hohenberger P, Huang P, Joensuu H, Jones RL, Jungels C, Kasper B, Kawai A, Le Cesne A, Le Grange F, Leithner A, Leonard H, Lopez Pousa A, **Martin Broto J**, Merimsky O, Merriam P, Miceli R, Mir O, Molinari M, Montemurro M, Oldani G, Palmerini E, Pantaleo MA, Patel S, Piperno-Neumann S, Raut CP, Ravi V, Razak ARA, Reichardt P, Rubin BP, Rutkowski P, Safwat AA, Sangalli C, Sapisochin G, Sbaraglia M, Scheipl S, Schöffski P, Strauss D, Strauss SJ, Sundby Hall K, Tap WD, Trama A, Tweddle A, van der Graaf WTA, Van De Sande MAJ, Van Houdt W, van Oortmerssen G, Wagner AJ, Wartenberg M, Wood J, Zaffaroni N, Zimmermann C, Casali PG, Dei Tos AP, Gronchi A. Epithelioid hemangi endothelioma, an ultra-rare cancer: a consensus paper from the community of experts. *ESMO Open.* 2021 Jun;6(3):100170. doi: 10.1016/j.esmoop.2021.100170.
 19. Rubio-San-Simón A, Hladun Alvaro R, Juan Ribelles A, Castañeda Heredia A, Guerra-García P, Verdú-Amorós J, Andrés M, Cañete A, Rives S, Pérez-Martínez A, Mora J, Patiño-García A, Lassaleta A, Llorc A, Ramírez M, Mata C, Gallego S, **Martín-Broto J**, Cruz O, Morales La Madrid A, Solano P, Martínez Romera I, Fernández-Teijeiro A, Bautista F, Moreno L. The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP). *Clin Transl Oncol.* 2021 Jun 2. doi: 10.1007/s12094-021-02649-y
 20. David S Moura, Maria Peña-Chilet, Juan Antonio Cordero Varela, Ramiro Alvarez-Alegret, Carolina Agra-Pujol, Francisco Izquierdo, Rafael Ramos, Luis Ortega-Medina, Francisco Martin-Davila, Carolina Castilla-Ramirez, Carmen Nieves Hernandez-Leon, Cleofe Romagosa, Maria Angeles Vaz Salgado, Javier Lavernia, Silvia Bagué, Empar Mayodormo-Aranda, Luis Vicioso, Jose Emilio Hernández Barceló, Jordi Rubio-Casadevall, Ana de Juan, Maria Concepcion Fiaño-Valverde, Nadia Hindi, Maria Lopez-Alvarez, Serena Lacerenza, Joaquin Dopazo, Antonio Gutierrez, Rosa Alvarez, Claudia Valverde, Javier Martinez-Trufero, **Javier Martín-Broto**. A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin. *Mol Oncol.* 2021 May 13. doi: 10.1002/1878-0261.12996.
 21. Michiel Van De Sande, William D Tap, Heather L Gelhorn, Xin Ye, Rebecca M Speck, Emanuela Palmerini, Silvia Stacchiotti, Jayesh Desai, Andrew J Wagner, Thierry Alcindor, Kristen Ganjoo, **Javier Martín-Broto**, Qiang Wang, Dale Shuster, Hans Gelderblom, John H Healey. Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial. (2021). *Acta Orthop.* 2021 May 12;1-7. doi: 10.1080/17453674.2021.1922161
 22. Nadia Hindi, **Javier Martin-Broto**. What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma? (2021). *Curr Opin Oncol.* 2021 May 10. doi: 10.1097/CCO.0000000000000742
 23. Nicholas M Bernthal, Geert Spierenburg, John H Healey, Emanuela Palmerini, Sebastian Bauer, TOPP Study Group; Hans Gelderblom, Eric L Staals, Julio Lopez-Bastida, Eva-Maria Fronk, Xin Ye, Petra Laeis, Michiel A J van de Sande. The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study. *Collaborator.* (2021). *Orphanet J Rare Dis.* 2021 Apr 29;16(1):191. doi: 10.1186/s13023-021-01820-6.
 24. Silvia Stacchiotti, Anna Maria Frezza, Jean-Yves Blay, Elizabeth H Baldini, Sylvie Bonvalot, Judith V M G Bovée, Dario Callegaro, Paolo G Casali, RuRu Chun-Ju Chiang, George D Demetri, Elisabeth G Demicco, Jayesh Desai, Mikael Eriksson, Hans Gelderblom, Suzanne George, Mrinal M Gounder, Alessandro Gronchi, Abha Gupta, Rick L Haas, Andrea Hayes-Jardon, Peter Hohenberger, Kevin B Jones, Robin L Jones, Bernd Kasper, Akira Kawai, David G Kirsch, Eugene S Kleinerman, Axel Le Cesne, Jiwon Lim, María Dolores Chirlaque López, Roberta Maestro, Rafael Marcos-Gragera, **Javier Martín Broto**, Tomohiro Matsuda, Olivier Mir, Shreyaskumar R Patel, Chandrajit P Raut, Albiruni R A Razak, Damon R Reed, Piotr Rutkowski, Roberta G Sanfilippo, Marta Sbaraglia, Inga-Marie Schaefer, Dirk C Strauss, Kirsten Sundby Hall, William D Tap, David M Thomas, Winette T A van der Graaf, Winan J van Houdt, Otto Visser, Margaret von Mehren, Andrew J Wagner, Breelyn A Wilky, Young-Joo Won, Christopher D M Fletcher, Angelo P Dei Tos, Annalisa Trama. Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology

- Society community of experts on the incidence threshold and the list of entities. (2021). *Cancer*. 2021 Apr 28;doi: 10.1002/cncr.33618.
25. Mrinal Gounder, Albiruni R Abdul Razak, Adrienne M Gilligan, Hoyee Leong, Xiwen Ma, Neeta Somaiah, Sant P Chawla, **Javier Martín-Broto**, Giovanni Grignani, Scott M Schuetze, Bruno Vincenzi, Andrew J Wagner, Bartosz Chmielowski, Robin L Jones, Jatin Shah, Sharon Shacham, Michael Kauffman, Richard F Riedel, Steven Attia. Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. (2021). *Future Oncol*. 2021 Apr 15;doi: 10.2217/fon-2021-0284
 26. Mahmoud Mohammadi, Nikki S IJzerman, Peter Hohenberger, Piotr Rutkowski, Robin L Jones, **Javier Martín-Broto**, Alessandro Gronchi, Patrick Schöffski, Nikolaos Vassos, Sheima Farag, Marco Baia, Astrid W Oosten, Neeltje Steeghs, Ingrid M E Desar, An K L Reyners, J W van Sandick, Esther Bastiaannet, Hans Gelderblom, Yvonne Schrage. Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. (2021). *Eur J Surg Oncol*. 2021 Mar 31;S0748-7983(21)00375-9. doi: 10.1016/j.ejso.2021.03.234.
 27. Robin L Jones, Andrew J Wagner, Akira Kawai, Kazuo Tamura, Ashwin Shahir, Brian A Van Tine, **Javier Martín-Broto**, Patrick M Peterson, Jennifer Wright, William D Tap. (2021). Prospective evaluation of doxorubicin cardiotoxicity in advanced soft tissue sarcoma patients treated in the ANNOUNCE Phase 3 randomized trial. *Clin Cancer Res*. 2021 Feb 25;clincanres.4592.2020. doi: 10.1158/1078-0432.CCR-20-4592.
 28. Javier Martínez-Trufero, Luis Miguel De Sande-González, Pablo Luna, **Javier Martín-Broto**, Rosa Álvarez, Gloria Marquina, Roberto Diaz-Beveridge, Andrés Poveda, Juana María Cano, Josefina Cruz-Jurado, Antonio López Pousa, María Angeles Vaz Salgado, Claudia M Valverde-Morales, Isabel Sevilla, Jerónimo Martínez-García, Jordi Rubio-Casadevall, Ana De Juan, Juan Antonio Carrasco, David S Moura, Ibon Gurruchaga-Sotes, Antonio Gutiérrez. (2021). A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study. *Cancers (Basel)*. 2021 Feb 14;13(4):792. doi: 10.3390/cancers13040792.
 29. Sylvie Bonvalot, Jay Wunder, Alessandro Gronchi, **Javier Martín Broto**, Robert Turcotte, Marco Rastrelli, Zsuzsanna Papai, Stefano Radaelli, Lars H Lindner, Felix Shumelinsky, Antonio Cubillo, Piotr Rutkowski, Clémentine Demaire, Daniëlle Strens, Georgi Nalbantov. (2021). Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: Results of a retrospective multicenter study. *Eur J Surg Oncol*. 2021 Feb 26;S0748-7983(21)00115-3. doi: 10.1016/j.ejso.2021.02.024.
 30. Ocadlikova D, Lecciso M, **Broto JM**, Scotlandi K, Cavo M, Curti A and Palmerini E (2021) Sunitinib Exerts *In Vitro* Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade. *Front. Immunol*. 12:577766. doi: 10.3389/fimmu.2021.577766
 31. P G Casali, A Le Cesne, A P Velasco, D Kotasek, P Rutkowski, P Hohenberger, E Fumagalli, I R Judson, A Italiano, H Gelderblom, N Penel, J T Hartmann, F Duffaud, D Goldstein, **J Martín-Broto**, A Gronchi, E Wardelmann, S Marréaud, J R Zalcborg, S Litière, J-Y Blay. (2021). Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS). *Ann Oncol*. 2021 Jan 19;S0923-7534(21)00012-0. doi: 10.1016/j.annonc.2021.01.004.
 32. den Hollander, D.; Fiore, M.; **Martín-Broto, J.**; Kasper, B.; Casado Herraéz, A.; Kulis, D.; Nixon, I.; Sodergren, S.C.; Eichler, M.; van Houdt, W.J.; Desar, I.M.E.; Ray-Coquard, I.; Piccinin, C.; Kosela-Paterczyk, H.; Miah, A.; Hentschel, L.; Singer, S.; Wilson, R.; van der Graaf, W.T.A.; Husson, O. (2021). Incorporating the Patient Voice in Sarcoma Research: How Can We Assess Health-Related Quality of Life in This Heterogeneous Group of Patients? A Study Protocol. *Cancers* 13, 1. <https://doi.org/10.3390/cancers13010001>
 33. Juan Ferré, A., Álvarez Álvarez, R., Casado Herráez, A; J. Cruz Jurado, A. Estival González, **J. Martín-Broto**, V. Martínez Marín, A. Moreno Vega, A. Sebio García & C. Valverde Morales. (2021). SEOM Clinical Guideline of management of soft-tissue sarcoma. *Clin Transl Oncol*. <https://doi.org/10.1007/s12094-020-02534-0>
 34. Hindi, Nadia; Carrasco García, Irene; Sánchez-Camacho, Alberto; Gutierrez, Antonio; Peinado, Javier; Rincón, Inmaculada; Benedetti, Johanna; Sancho, Pilar; Santos, Paloma; Sánchez-Bustos, Paloma; Marcilla, David; Encinas, Victor; Chacon, Sara; Muñoz-Casares, Cristobal; Moura, David; **Martín-Broto, Javier**. (2020). "Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center". *Cancers* 12: 3740. <https://doi.org/10.3390/cancers12123740>
 35. **Martín-Broto J**, Pousa AL, Brohl AS, Van Tine BA, Powers B, Stacchiotti S, Blay JY, Hu JS, Oakley GJ 3rd, Wang H, Szpurka AM, Levy DE, Mo G, Ceccarelli M, Jones RL (2021). Circulating Tumor Cells and

- Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. *Mol Cancer Ther.* 20(1):132-141. doi: 10.1158/1535-7163.MCT-20-0441. Epub 2020 Nov 11. PMID: 33177152.
36. **Martin-Broto J**, Hindi N, Grignani G, Martinez-Trufero J, Redondo A, Valverde C, Stacchiotti S, Lopez-Pousa A, D'Ambrosio L, Gutierrez A, Perez-Vega H, Encinas-Tobajas V, de Alava E, Collini P, Peña-Chilet M, Dopazo J, Carrasco-Garcia I, Lopez-Alvarez M, Moura DS, Lopez-Martin JA. (2020) Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial. *J Immunother Cancer.* 8(2):e001561. doi: 10.1136/jitc-2020-001561. PMID: 33203665; PMCID: PMC7674086.
 37. Axel LeCesne, **Javier Martin-Broto**, Peter Reichardt, Piero Picci and Jean-Yves Blay. (2020). Current treatment patterns in advanced soft tissue sarcoma: real-world evidence of over 5,000 European patients. *Cancer & Chemoth Rev, Vol15, N3 (Suppl 1).* ISSN:1885-740X.
 38. Alessandro Gronchi; Sylvie Bonvalot; Andres Poveda Velasco; Dusan Kotasek; Piotr Rutkowski; Peter Hohenberger; Elena Fumagalli; Ian R. Judson; Antoine Italiano; Hans J. Gelderblom; Frits van Coevorden; Nicolas Penel; Hans-Georg Kop; Florence Duffaud; David Goldstein; **Javier Martin Broto et al.** (2020). Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. *JAMA Surg.* 155(6):e200397. doi:10.1001/jamasurg.2020.0397
 39. Demetri GD, Antonescu CR, Bjerkeheggen B, Bovée JVMG, Boye K, Chacón M, Dei Tos AP, Desai J, Fletcher JA, Gelderblom H, George S, Gronchi A, Haas RL, Hindi N, Hohenberger P, Joensuu H, Jones RL, Judson I, Kang YK, Kawai A, Lazar AJ, Le Cesne A, Maestro R, Maki RG, **Martín J et al.** (2020). Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. *Ann Oncol.* ;31(11):1506-1517. doi: 10.1016/j.annonc.2020.08.2232. Epub 2020 Sep 3. PMID: 32891793.
 40. **Martin-Broto J**, Hindi N, Lopez-Pousa A, Peinado-Serrano J, Alvarez R, Alvarez-Gonzalez A, Italiano A, Sargos P, Cruz-Jurado J, Isern-Verdum J, Dolado MC, Rincon-Pérez I, Sánchez-Busto P et al. (2020). Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients with Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial. *JAMA Oncol.* 6(4):535-541. doi:10.1001/jamaoncol.2019.6584
 41. **Martin-Broto J**; J Cruz; N Penel; A Le Cesne; N Hindi; P Luna; DS Moura; D Bernabeu; E de Alava; JA Lopez Guerrero; J Dopazo; M Peña Chilet; A Gutierrez; P Collini; M Karanian; A Redondo; A Lopez Pousa; G Grignani; J Diaz Martín; D Marcilla; A Fernandez Serra; C Gonzalez Aguilera; PG Casali; JY Blay; S Stacchiotti. (2020). Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. *Lancet Oncol.* 21(3):456-466. doi: 10.1016/S1470-2045(19)30826-5.
 42. **Javier Martin-Broto**, Nadia Hindi, Samuel Aguiar Jr, Ronald Badilla-González, Victor Castro-Oliden et al. (2020). SARCOMA EUROPEAN & LATIN AMERICAN NETWORK (SELNET) RECOMMENDATIONS ON PRIORITIZATION IN SARCOMA CARE DURING COVID-19 PANDEMIC. *Oncologist* 25(10). doi: 10.1634/theoncologist.2020-0516
 43. Antonio Fernandez-Serra, David S. Moura, María Dolores Sanchez-Izquierdo, Silvia Calabuig-Fariñas, Maria Lopez-Alvarez, Andrea Martínez-Martínez, Irene Carrasco-Garcia, Marta Ramírez-Calvo, Elena Blanco-Alcaina, Raquel López-Reig, Antonia Obrador-Hevia, Regina Alemany, Antonio Gutierrez, Nadia Hindi, Andres Poveda, Jose A. Lopez-Guerrero and **Javier Martin-Broto.** (2020). Prognostic Impact of let-7e MicroRNA and Its Target Genes in Localized High-Risk Intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study. *Cancers* 12(10), 2979; <https://doi.org/10.3390/cancers12102979>
 44. Marco Perez, José Manuel García-Heredia, Blanca Felipe-Abrio, Sandra Muñoz-Galván, **Javier Martín-Broto**, Amancio Carnero. (2020). Sarcoma stratification by combined pH2AX and MAP17 (PDZK11P1) levels for a better outcome on doxorubicin plus olaparib treatment. *Signal Transduct Target Ther;* 5(1):195. doi: 10.1038/s41392-020-00246-z.
 45. Dario Callegaro, Chandrajit P Raut, Emily Z Keung, Teresa Kim, Cecile Le Pechoux, **Javier Martin-Broto, et al.** (2020). Strategies for care of patients with gastrointestinal stromal tumor or soft tissue sarcoma during COVID-19 pandemic: A guide for surgical oncologists. *J Surg Oncol* 123(1); pp 12-23. doi: 10.1002/jso.26246
 46. Esther Martinez-Font, Marina Pérez-Capó, Rafael Ramos, Irene Felipe, Carmen Garcías, Pablo Luna, Josefa Terrasa, **Javier Martín-Broto et al.** (2020). Impact of Wnt/β-Catenin Inhibition on Cell Proliferation through CDC25A Downregulation in Soft Tissue Sarcomas. *Cancers (Basel)* 12(9):E2556. doi: 10.3390/cancers12092556
 47. Luis Miguel de Sande González, **Javier Martin-Broto**, Bernd Kasper, Jean-Yves Blay, Axel Le Cesne. (2020). Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma. *Expert Rev Anticancer Ther* 20(11). doi: 10.1080/14737140.2020.1822744

48. **Javier Martín-Broto**, David S Moura, Brian A Van Tine. (2020). Facts and Hopes in Immunotherapy of Soft Tissue Sarcomas. *Clin Cancer Res* 26(22). doi: **10.1158/1078-0432.CCR-19-3335**.
49. **Javier Martín-Broto** and David S. Moura. (2020). New drugs in gastrointestinal stromal tumors. *Curr Opin Oncol*. doi: **10.1097/CCO.0000000000000642**
50. Paula Martínez-Delgado, Serena Lacerenza, Antonia Obrador-Hevia, Maria Lopez-Alvarez, José L. Mondaza-Hernandez, Elena Blanco-Alcaina, Paloma Sanchez-Bustos, Nadia Hindi, David S. Moura and **Javier Martín-Broto**. (2020). Cancer Stem Cells in Soft-Tissue Sarcomas. *Cells* 2020, 9(6), 1449. Doi: **10.3390/cells9061449**.
51. Moura DS, Sanchez-Bustos P, Fernandez-Serra A, Lopez-Alvarez M, Mondaza-Hernandez JL, Blanco-Alcaina E, Gavilan-Naranjo A, Martinez-Delgado P, Lacerenza S, Santos-Fernandez P, Carrasco-Garcia I, Hidalgo-Rios S, Gutierrez A, Ramos R, Hindi N, Taron M, Lopez-Guerrero JA, **Martín-Broto J**. (2020). *CUL4A*, *ERCC5*, and *ERCC1* as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) Study. *Cancers (Basel)* 12(5). doi: **10.3390/cancers12051128**.
52. Alessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo, **Javier Martín Broto** et al. (2020). Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. *J Clin Oncol*. 38(19). doi: **10.1200/JCO.19.03289**.
53. Tap WD, Wagner AJ, Schöffski P, **Martín-Broto J** et al. (2020). Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial; ANNOUNCE Investigators. *JAMA* 323(13):1266-1276. doi: **10.1001/jama.2020.1707**.
54. **Martín-Broto J**, Reichardt P, Jones RL, Stacchiotti S. (2020). Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype. *Expert Rev Anticancer Ther* 20(2020); 1-14. doi: **10.1080/14737140.2020.1753510**.
55. D'Ambrosio L, Touati N, Blay JY, Grignani G, Flippot R, Czarnecka AM, Piperno-Neumann S, **Martín-Broto J** et al. (2020). Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. *Cancer* 2020 126(11). Doi: **10.1002/cncr.32795**.
56. Anderton J, Moroz V, Marec-Bérard P, Gaspar N, Laurence V, **Martín-Broto J** (2020). International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours-EURO EWING 2012 Protocol. *Trials* 2020 21(1):96. DOI: **10.1186/s13063-019-4026-8**.
57. Napolitano A, Provenzano S, Colombo C, Vitellaro M, Brunello A, Badalamenti G, Nannini M, Ibrahim T, Hohenberger P, Gasperoni S, Gennatas S, Jones RL, Hindi N, **Martín-Broto J** et al. (2020). Familial adenomatous polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. *ESMO OPEN* 5(1). doi: **10.1136/esmoopen-2019-000604**.
58. Serrano C; Vivancos A; López-Pousa A; Matito J; Mancuso FM; Valverde C; Quiroga S; Landolfi S; Castro S; Dopazo C; Sebío A; Virgili AC; Menso MM; **Martín-Broto J** et al. (2020). Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors. *BMC Cancer* 2020 20(1):99. doi: **10.1186/s12885-020-6597-x**.
59. **Martín-Broto J**. (2020). Risk-based treatment of non-rhabdomyosarcoma soft-tissue sarcoma in children. *Lancet Oncol* 2020 21(1):16-17. doi: **10.1016/S1470-2045(19)30679-5**.
60. Álvarez Álvarez R, Cruz Jurado J, Del Muro Solans XG, Giner JL, López Pousa A, **Martín-Broto J**, Valverde CM. (2019). Optimization of the Therapeutic Approach to Patients with Sarcoma: Delphi Consensus. *Sarcoma* vol2019. doi: **10.1155/2019/4351308**. PMID: 31975783; PMCID: PMC6959159.
61. **Martín-Broto J**, Hindi N, Moura DS. (2019). Which goals should we pursue in each line of treatment for advanced soft tissue sarcoma? *Future Oncology* 15(26). doi: **10.2217/fon-2019-0490**.
62. Stacchiotti S, Ferrari S, Redondo A, Hindi N, Palmerini E, Vaz Salgado MA, Frezza AM, Casali PG, Gutierrez A, Lopez-Pousa A, Grignani G, Italiano A, LeCesne A, Dumont S, Blay JY, Penel N, Bernabeu D, de Alava E, Karanian M, Morosi C, Bric S, Dagrada GP, Vallacchi V, Castelli C, Brenca M, Racanelli D, Maestro R, Collini P, Cruz J, **Martín-Broto J**. (2019). Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. *Lancet Oncol*. 20(9):1252-1262. doi:**10.1016/S1470-2045(19)30319-5**.
63. Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, Alcindor T, Ganjoo K, **Martín-Broto J** et al. (2019). Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. *Lancet*. 394(10197):478-487. doi: **10.1016/S0140-6736(19)30764-0**.

64. **Javier Martín-Broto**, Silvia Stacchiotti, Antonio Lopez-Pousa, Andres Redondo *et al.* (2019). Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. *Lancet Oncol.* 20(1):134-144. doi: [10.1016/S1470-2045\(18\)30676-4](https://doi.org/10.1016/S1470-2045(18)30676-4).
65. Gronchi A, Hindi N, Cruz J, Blay JY, Lopez-Pousa A, Italiano A, Alvarez R, Gutierrez A, Rincón I, Sangalli C, Pérez Aguiar JL, Romero J, Morosi C, Sunyach MP, Sanfilippo R, Romagosa C, Ranchere-Vince D, Dei Tos AP, Casali PG, **Martín-Broto J.** (2019). Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups. *EClinicalMedicine.* 9:35-43. doi: [10.1016/j.eclinm.2019.03.007](https://doi.org/10.1016/j.eclinm.2019.03.007).
66. **Martín-Broto J.** Moura DS, Hindi N. (2019). Pazopanib in the treatment of advanced solitary fibrous tumour - Authors' reply. *Lancet Oncol.* 20(3):e128. doi: [10.1016/S1470-2045\(19\)30080-4](https://doi.org/10.1016/S1470-2045(19)30080-4)
67. **Martín-Broto J.** Hindi N. In Reply. (2019). *Oncologist* 24(6): 401-402. doi: [10.1634/theoncologist.2019-0052](https://doi.org/10.1634/theoncologist.2019-0052)

Full list of publications: <https://publons.com/researcher/1510987/javier-martin-broto/>

Projects and Clinical Trials in the past 5 years

Project Name: The role of solitary fibrous tumor secretome in matrix remodeling and cell-to-cell communication

PI: Javier Martín Broto

Date: 2022-2024

Budget: 26.500,00€

Funding Entity: Asociacion aragonesa de pacientes con sarcomas y tumores raros/ GEIS

Project Name: Targeting tumor-associated macrophages as a new strategy to improve first-line drugs activity in advanced leiomyosarcoma

PI: Javier Martín Broto

Date: 2022-2024

Budget: 15.000,00€

Funding Entity: GEIS (Beca Buesa)

Project Name: Preclinical study to test the activity of Ecubectedin/PM-14 in monotherapy and in combination with radiotherapy in sarcomas

PI: Javier Martín Broto

Date: 2022-2024

Budget: 48.900,00€

Funding Entity: PharmaMar

Project Name: *Phase I-II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas*

Collaborator Investigator: Javier Martín Broto

Date: 2020-2021

Budget: 50.000\$

Funding Entity: *Sarcoma Foundation of America*

Project Name: *Observational and translational multicentre study of cancer patients infected by covid-19: a european study by euracan network*

PI: Javier Martín Broto

Budget: 46.000,00€

Funding Entity: *Programa ayudas a proyectos de investigación sobre el sars-cov-2 y la enfermedad covid-19 en régimen de concurrencia no competitiva, para agentes públicos del sistema andaluz del conocimiento con cargo a fondos feder*

Project Name: *Improving neoadjuvant therapy in high-risk sarcomas*

Collaborator Investigator: Javier Martín Broto

Date: 2019-2023

Budget: 559.250€

Funding Entity: *Foundation AECC (Cancer Research UK)*

Project Name: *Beca Sara Borrell (David da Silva Moura)*

PI: Javier Martín Broto

Funding Entity: *ISCIII*

Project Name: *Intensificación Carlos III*

PI: Javier Martín Broto

Funding Entity: *ISCIII*

Project Name: *SARCOVID*

PI: Javier Martín Broto

Budget: 133,710.00 €

Funding Entity: *Pfizer's Global Medical Grants program: Vaccine Preventable Diseases – COVID-19 Competitive Grant Program*

Project Name: *Sarcoma as a model to improve diagnosis and clinical care of rare tumors through a European and Latin American multidisciplinary network (SELNET)*

Principal Investigator: Javier Martín Broto

Date: 2019-2023

Budget: 3.100.000,00€

Funding Entity: *Horizon 2020 - Translational collaborative cancer research between Europe and the Community of Latin American and Caribbean States (CELAC)*

Project Name: *PP2A inhibition as a mechanism to enhance doxorubicin activity*

Collaborator Investigator: Javier Martín Broto

Date: 2020-2023

Budget: 340.000€

Funding Entity: *GEIS*

Project Name: *Efficacy of selinexor plus gemcitabine in selected advanced soft-tissue sarcoma and osteosarcoma: blocking nuclear export as a mechanism to improve gemcitabine activity*

Collaborator Investigator: Javier Martín Broto

Date: 2020-2023

Budget: 168.800€

Funding Entity: *GEIS*

Project Name: *Agentes antiangiogénicos en Tumor Fibroso Solitario: nuevas ideas en el mecanismo de acción*

Principal Investigator: Javier Martín Broto

Date: 2019-2022

Budget: 111.000,00€

Funding Entity: *Instituto de Salud Carlos III. Subprograma de proyectos de investigación en salud (AES 2018)*

Project Name: *Phase I clinical trial of Olaratumab plus Trabectedin in advanced soft-tissue sarcoma patients (OLATRASTS)*

Principal Investigator: Javier Martín Broto

Date: 2019 - 2020

Budget (Translational Research): 75.000,00€

Funding Entity: *GEIS*

Project Name: *New insights in the mechanisms of action of cisplatin in rhabdomyosarcomas: waking up an old drug for a fresh purpose*

Principal Investigator: Javier Martín Broto

Date: 2018 - 2020

Budget: 52.000,00€

Funding Entity: *Movimiento Iván Pérez - GEIS*

Project Name: *Exploring vasculature-related targets in angiosarcoma: an open road to new clinical trials*

Investigator: Javier Martín Broto

Date: 2018 - 2020

Budget: 27.000,00€

Funding Entity: *Vyda - GEIS*